Philippe Rousselot

Functional G-CSF pathways in t(8;21) leukemic cells allow for differentiation induction and degradation of AML1-ETO.

H. Dombret, P. Fenaux, P. Rousselot, 2000, The hematology journal : the official journal of the European Haematology Association.

Defective blood dendritic cells in chronic myeloid leukemia correlate with high plasmatic VEGF and are not normalized by imatinib mesylate

J. Cayuela, H. Dombret, A. Toubert, 2004, Leukemia.

Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years.

J. Cayuela, G. Marit, F. Mahon, 2007, Blood.

The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts.

J. Radich, H. Kantarjian, D. B. Yehuda, 2013, Blood.

Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years.

J. Cayuela, J. Reiffers, P. Rousselot, 2007, Blood.

Usefulness of the 2012 European CVD risk assessment model to identify patients at high risk of cardiovascular events during nilotinib therapy in chronic myeloid leukemia

H. Dombret, E. Messas, P. Rousselot, 2014, Leukemia.

Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome – positive acute lymphoblastic leukemia : results of the GRAAPH-2003 study

J. Cayuela, H. Dombret, E. Macintyre, 2007 .

Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study.

J. Cayuela, H. Dombret, E. Macintyre, 2007, Blood.